Shares of Trovagene Inc. (NASDAQ:TROV) have received a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the firm. Five research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.25.

TROV has been the topic of several recent research reports. Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Piper Jaffray Cos. set a $4.00 price objective on Trovagene and gave the stock a “hold” rating in a research report on Friday, August 5th. Maxim Group restated a “buy” rating and issued a $9.00 price objective on shares of Trovagene in a research report on Thursday, October 6th. Finally, Cantor Fitzgerald upgraded Trovagene from a “hold” rating to a “buy” rating and upped their price objective for the stock from $5.00 to $7.00 in a research report on Monday, August 8th.

Several hedge funds and other institutional investors have recently made changes to their positions in TROV. Geode Capital Management LLC raised its position in shares of Trovagene by 1.3% in the first quarter. Geode Capital Management LLC now owns 183,442 shares of the company’s stock worth $853,000 after buying an additional 2,363 shares during the period. BlackRock Investment Management LLC raised its position in shares of Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock worth $513,000 after buying an additional 5,964 shares during the period. Rhumbline Advisers raised its position in shares of Trovagene by 39.3% in the second quarter. Rhumbline Advisers now owns 39,171 shares of the company’s stock worth $177,000 after buying an additional 11,044 shares during the period. First Heartland Consultants Inc. purchased a new position in Trovagene during the second quarter valued at approximately $103,000. Finally, Vanguard Group Inc. increased its position in Trovagene by 3.2% in the second quarter. Vanguard Group Inc. now owns 979,014 shares of the company’s stock valued at $4,435,000 after buying an additional 30,369 shares in the last quarter. Hedge funds and other institutional investors own 31.05% of the company’s stock.

Shares of Trovagene (NASDAQ:TROV) traded up 1.6683% during midday trading on Monday, reaching $4.1684. 50,767 shares of the company traded hands. The stock has a 50 day moving average price of $4.69 and a 200 day moving average price of $4.88. The firm’s market capitalization is $125.66 million. Trovagene has a 1-year low of $2.85 and a 1-year high of $7.18.

Trovagene (NASDAQ:TROV) last issued its earnings results on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.03. Trovagene had a negative net margin of 8,495.00% and a negative return on equity of 80.13%. Analysts expect that Trovagene will post ($1.34) earnings per share for the current fiscal year.

About Trovagene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

5 Day Chart for NASDAQ:TROV

Receive News & Stock Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related stocks with our FREE daily email newsletter.